The company presented data on its COVID-19 vaccine candidate at the European Society of Medicine’s General Assembly. GOVX is seeing trading lower by 7% in today’s pre-market. It has gained almost 50% in just one day. The stock shot up on Friday last week. Will there be any other reason to not invest yet? The company has only $36.131 million of market capitalization.
According to Geovax, this could mean that a universal vaccine could be developed to protect against future strains of the coronavirus. Currently, the only way to protect against the current strains is through a COVID-19-based vaccine. Studies to date have shown that MVA can be used as a template for the design and development of next-generation vaccines that contain multiple coronavirus proteins. The combination of the S protein and the M and E protein targets produces optimal immunogenicity.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.